|

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

RECRUITINGPhase 2Sponsored by Vertex Pharmaceuticals Incorporated
Actively Recruiting
PhasePhase 2
SponsorVertex Pharmaceuticals Incorporated
Started2026-04-16
Est. completion2029-03-02
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT07501702

Summary

The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Key Inclusion Criteria:

* Age 18-80 years
* Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
* Additional inclusion criteria are defined in the protocol

Key Exclusion Criteria:

* History of thymic surgery within 6 months of screening
* History of malignancy within the last 5 years
* Additional exclusion criteria are defined in the protocol

Other protocol defined Inclusion/Exclusion criteria will apply.

Conditions2

CancerMyasthenia Gravis, Generalized

Interventions1

Povetacicept

Locations3 sites

Florida

1 site
Quantix Research
Miami, Florida, 33173

Hawaii

1 site
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817

South Carolina

1 site
Clinical Trials of South Carolina - Neurology
Charleston, South Carolina, 29406

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.